Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 15.59M shares rose 0.8% year over year, behind the +3.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at -27.2% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.8% toward the trailing-twelve-month pace of +3.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
15.59M+0.6% QoQ
Last fiscal yearDec 2025
15.49M+7.0% YoY
LTMMar 2026
15.5M+3.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.8%——
1 year+7.0%——
3-year CAGR-27.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
15.49M USD
Year-over-year change
+7.0%
4-year CAGR
-20.1%

Weighted Avg Shares (Diluted) vs competitors

How INBX compares with its peers on the latest reported figures

  • INBX's LTM Mar 2026 weighted avg shares (diluted) of 15.5M shares is the lowest of the 7 companies compared; the peer median is 67.25M shares.
  • Its year-over-year change of +3.0% is the 6th highest of 7, against a peer median of +11.2%.
  • Over three fiscal years its annual growth of -27.2% compares with a peer median of +14.6%.
INBX Competitors Peer median
Weighted Avg Shares (Diluted) for INBX and competitors
Company Period LTM YoY 3-year CAGR
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
IMTXImmatics N.V.LTM Mar 2026125.95M +13.3%+21.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
JANXJanux Therapeutics, Inc.LTM Mar 202662.14M +9.2%+14.3%
GENBGenerate Biomedicines, Inc.FY202550.09M -60.7%—
TECXTectonic Therapeutic, Inc.LTM Mar 202618.62M +21.3%+71.3%
INBXInhibrx Biosciences, Inc.LTM Mar 202615.5M +3.0%-27.2%
Peer median (excluding INBX) 67.25M+11.2%+14.6%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.